Exxua Tablet, Extended Release
Product Images NDC 23594-150

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Exxua (NDC 23594-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aytu Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Exxua 1)

Chemical structure of gepirone hydrochloride, showing its molecular formula C19H29N5O2 · HCl with ring structures and functional groups.*

FDA Label Image

Figure 1 (Exxua 2)

A forest plot chart showing the mean effect and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of EXXUA (gepirone) across population subgroups including race, age, renal impairment, and hepatic impairment. The x-axis represents change relative to reference values, illustrating variability among subgroups.*

FDA Label Image

Figure 2 (Exxua 3)

A forest plot chart depicting the mean effect and 90% confidence intervals for the pharmacokinetic parameters Cmax and AUC of gepirone 36.3 mg when administered with interacting drugs ketoconazole, lithium, paroxetine, verapamil, and warfarin. The chart shows changes relative to reference values, illustrating drug interaction effects.*

FDA Label Image

Figure 3 (Exxua 4)

A line graph comparing the least squares mean change from baseline in HAMD-17 total score over 8 weeks between EXXUA (gepirone) extended release tablets at doses of 18.2 to 72.6 mg/day (116 patients) and placebo (122 patients). The graph shows a greater reduction in HAMD-17 scores for EXXUA compared to placebo over time, with error bars representing standard error.*

FDA Label Image

18.2 mg (Exxua 5)

Label for EXXUA 18.2 mg extended-release oral tablets containing gepirone. The label shows the NDC 23594-150-30 and indicates the package contains 30 tablets. Manufactured by Mission Pharmacal Company and distributed by Aytu Therapeutics, LLC, with storage instructions and a note about the Medication Guide.*

FDA Label Image

36.3 mg (Exxua 6)

Label for EXXUA (gepirone) extended-release tablets, 36.3 mg strength. The label indicates 30 tablets per bottle and is for oral use. It features the NDC 23594-151-30 and states the product is distributed by Aytu Therapeutics, LLC. The label includes a warning about dispensing with the Medication Guide and storage instructions.*

FDA Label Image

54.5 mg (Exxua 7)

EXXUA 54.5 mg extended-release tablets label showing the dosage strength, NDC number 23594-152-30, and a package count of 30 tablets. The label includes the generic name gepirone, manufacturer Aytu Therapeutics, LLC, and storage instructions. The label features a barcode and the Rx only designation.*

FDA Label Image

72.6 mg (Exxua 8)

EXXUA (gepirone) extended-release tablets 72.6 mg strength, oral dosage form, in a 30-tablet package. The label indicates it is a prescription drug distributed by Aytu Therapeutics, LLC. The label includes an NDC number 23594-153-30, a barcode, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.